Facility Registration Violations, Refusa
Indian API manufacturer Jagsonpal Pharmaceuticals was issued a Warning Letter by the US FDA in
Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
